Chiron Makes Genital Herpes Vaccine Announcement.EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 25, 1996--Chiron Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CHIR CHIR Chiricahua National Monument (US National Park Service) ) announced today that its preliminary analysis of data available from prophylactic genital herpes Genital Herpes Definition Genital herpes is a sexually transmitted disease caused by a herpes virus. The disease is characterized by the formation of fluid-filled, painful blisters in the genital area. vaccine trials conducted by its Chiron Vaccines business unit does not indicate efficacy for the product. Based upon these results, the company does not intend to pursue a Product License Application (PLA (Programmable Logic Array) A type of programmable logic chip (PLD) that contained arrays of programmable AND and OR gates. PLAs are no longer used. See PLD. (language, music) Pla - A high-level music programming language, written in SAIL. ) for this product. Further analysis of the data is underway. Complete results will be reported by clinical investigators in appropriate scientific forums. Chiron Corp., headquartered in Emeryville, near San Francisco, is a science-driven healthcare company that combines diagnostic, vaccine and therapeutic strategies for controlling disease. Chiron participates in four global markets: diagnostics, including immunodiagnostics, critical care diagnostics, and new quantitative probe tests; pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. and adult vaccines; therapeutics, with an emphasis on oncology and infectious diseases; and ophthalmic surgical products for the correction of vision. Chiron also has research programs underway in gene therapy and gene transfer, combinatorial transfer, combinatorial chemistry, cardiovascular disease and critical care. Chiron had total revenues of $1.1 billion for the year ended Dec. 31, 1995. CONTACT: Chiron Corp., Emeryville Larry Kurtz, 510/923-2476 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion